The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]

Medical Professionals Become an LDN Specialist [More Details]

Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice

CNS Neurosci Ther
21 May 2021

Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy

Int Immunopharmacol
11 May 2021

Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients

Hum Psychopharmacol
24 May 2021

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and Beta-Endorphin

24 May 2021

Addiction Medication Promising for Chronic, Refractory Pain (News)

Submitted by baileylynn_100964 on Sun, 05/02/2021 - 00:28

Addiction Medication Promising for Chronic, Refractory Pain

Medscape Medical News
01 May 2021

Preliminary data from a retrospective chart review of patients with chronic pain showed those who received LDN experienced significant improvement in both pain and disability.


The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia

Front Psychiatry
16 February 2021

Nutrichem's LDN Book Event with Dr Adam Livingston (Low dose naltrexone) from LDN Research Trust on Vimeo.

Dr. Adam Livingston, PharmD, BSc., RPh.

Low-dose Naltrexone (LDN) Prescription Basics